Fresh Tracks Therapeutics Inc   (FRTX)
Other Ticker:  
Price: $0.9070 $0.01 0.666%
Day's High: $0.9111 Week Perf: 0.78 %
Day's Low: $ 0.90 30 Day Perf: -7.45 %
Volume (M): 2 52 Wk High: $ 3.14
Volume (M$): $ 2 52 Wk Avg: $0.79
Open: $0.91 52 Wk Low: $0.45

 Market Capitalization (Millions $) 5
 Shares Outstanding (Millions) 6
 Employees -
 Revenues (TTM) (Millions $) 10
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Fresh Tracks Therapeutics Inc
Fresh Tracks Therapeutics Inc is a biotechnology company that focuses on the development of innovative therapies for various medical conditions. They are committed to discovering and advancing novel treatments that can improve the lives of patients. The company utilizes cutting-edge research and technology to identify potential drug candidates and conducts rigorous clinical trials to determine their safety and efficacy. Fresh Tracks Therapeutics Inc aims to address unmet medical needs and bring new treatments to market that have the potential to make a significant impact in healthcare.

   Company Address: 2000 Central Avenue, Boulder, 80301 CO
   Company Phone Number: 505-4755   Stock Exchange / Ticker: NASDAQ FRTX
   FRTX is expected to report next financial results on March 29, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report


Fresh Tracks Therapeutics Moves Listing to OTC Pink Market

Published Tue, Dec 19 2023 10:19 PM UTC

BOULDER, Colo., Dec. 19, 2023 - Fresh Tracks Therapeutics, Inc. (OTC Pink: FRTX), a leading biotechnology company, has announced that its common stock has been suspended from trading on The Nasdaq Capital Market. The company's stock will now be quoted on the OTC Pink market under the same trading symbol, FRTX. Fresh Tracks has also withdrawn its appeal of Nasdaq's decis...

Fresh Tracks Therapeutics Inc

Fresh Tracks Therapeutics Inc Set to Astound with Unexpected Performance throughout Q3 2023

Fresh Tracks Therapeutics Inc. is a biotechnology and pharmaceutical company that has shown remarkable growth and profitability in recent years. Despite the challenging business environment faced by many companies in the industry, Fresh Tracks Therapeutics Inc. has managed to achieve impressive results.
In its most recent fiscal period, the company saw an astounding revenue improvement of 1534.568%, reaching $7.94 million. This is a significant increase compared to the previous year, where revenue was only $0.05 million. This exponential growth can be attributed to the company's successful strategies and execution.

Fresh Tracks Therapeutics Inc

Fresh Tracks Therapeutics Inc Overcomes Challenges and Shows Promising Progress in Q2 2023 Earnings Season

Fresh Tracks Therapeutics Inc, a pharmaceutical company, recently released its financial results for the time-frame ending June 30, 2023. The company showed improvements in several key areas, but also faced challenges in terms of revenue and stock performance.
In terms of earnings per share (EPS), Fresh Tracks Therapeutics Inc experienced a decrease in loss per share. The loss per share decreased from $-0.43 a year ago to $-0.39 in the most recent reporting period. This is a positive sign, indicating that the company is making progress in reducing its losses.

Fresh Tracks Therapeutics Inc

Headline: Fresh Tracks Therapeutics Inc Faces Significant Financial Setback in Q1 20232.

Fresh Tracks Therapeutics Inc Experiences a Disastrous Fiscal Period
Fresh Tracks Therapeutics Inc recently declared its most recent fiscal period, and the results were far from impressive. The company reported a revenue decrease of -90.217% to $0.01 million, and its shortfall per share expanded to $-1.14 from the same reporting season a year ago. This marks a significant decline from its previous reporting season, where it boasted a shortfall per share of $-1.70, and revenue tumbled by -99.561% from $2.05 million.
The poor performance in revenue was not the only area where the company suffered. Fresh Tracks Therapeutics Inc reported a net deficit of $-4.276 million in the most recent fiscal period, which is still an improvement from its deficit of $-9.410 million in the same reporting season a year ago. Nevertheless, this data is still concerning for investors, and it highlights several issues the company needs to address to improve its financial position.


Fresh Tracks Therapeutics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com